Vascular remodeling is governed by a VEGFR3-dependent fluid shear stress set point

  1. Nicolas Baeyens
  2. Stefania Nicoli
  3. Brian G Coon
  4. Tyler D Ross
  5. Koen Van den Dries
  6. Jinah Han
  7. Holly M Lauridsen
  8. Cecile O Mejean
  9. Anne Eichmann
  10. Jean-Leon Thomas
  11. Jay D Humphrey
  12. Martin A Schwartz  Is a corresponding author
  1. Yale University School of Medicine, United States
  2. Yale University School of Engineering and Applied Science, United States

Abstract

Vascular remodeling under conditions of growth or exercise, or during recovery from arterial restriction or blockage is essential for health, but mechanisms are poorly understood. It has been proposed that endothelial cells have a preferred level of fluid shear stress, or 'set point,' that determines remodeling. We show that human umbilical vein endothelial cells respond optimally within a range of fluid shear stress that approximate physiological shear. Lymphatic endothelial cells, which experience much lower flow in vivo, show similar effects but at lower value of shear stress. VEGFR3 levels, a component of a junctional mechanosensory complex, mediate these differences. Experiments in mice and zebrafish demonstrate that changing levels of VEGFR3/Flt4 modulates aortic lumen diameter consistent with flow-dependent remodeling. These data provide direct evidence for a fluid shear stress set point, identify a mechanism for varying the set point, and demonstrate its relevance to vessel remodeling in vivo.

Article and author information

Author details

  1. Nicolas Baeyens

    Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Stefania Nicoli

    Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Brian G Coon

    Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Tyler D Ross

    Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Koen Van den Dries

    Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Jinah Han

    Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Holly M Lauridsen

    Department of Biomedical Engineering, Yale University School of Engineering and Applied Science, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Cecile O Mejean

    Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Anne Eichmann

    Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Jean-Leon Thomas

    Department of Neurology, Yale University School of Medicine, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Jay D Humphrey

    Department of Biomedical Engineering, Yale University School of Engineering and Applied Science, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Martin A Schwartz

    Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, United States
    For correspondence
    martin.schwartz@yale.edu
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: All animal experiments were performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and approved by the Institutional Care and Use Committee of Yale University (protocol #11406).

Copyright

© 2015, Baeyens et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,591
    views
  • 1,045
    downloads
  • 205
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Nicolas Baeyens
  2. Stefania Nicoli
  3. Brian G Coon
  4. Tyler D Ross
  5. Koen Van den Dries
  6. Jinah Han
  7. Holly M Lauridsen
  8. Cecile O Mejean
  9. Anne Eichmann
  10. Jean-Leon Thomas
  11. Jay D Humphrey
  12. Martin A Schwartz
(2015)
Vascular remodeling is governed by a VEGFR3-dependent fluid shear stress set point
eLife 4:e04645.
https://doi.org/10.7554/eLife.04645

Share this article

https://doi.org/10.7554/eLife.04645

Further reading

    1. Cell Biology
    2. Medicine
    Shuo He, Lei Huang ... Jinlong He
    Research Article

    Disturbed shear stress-induced endothelial atherogenic responses are pivotal in the initiation and progression of atherosclerosis, contributing to the uneven distribution of atherosclerotic lesions. This study investigates the role of Aff3ir-ORF2, a novel nested gene variant, in disturbed flow-induced endothelial cell activation and atherosclerosis. We demonstrate that disturbed shear stress significantly reduces Aff3ir-ORF2 expression in athero-prone regions. Using three distinct mouse models with manipulated Aff3ir-ORF2 expression, we demonstrate that Aff3ir-ORF2 exerts potent anti-inflammatory and anti-atherosclerotic effects in Apoe-/- mice. RNA sequencing revealed that interferon regulatory factor 5 (Irf5), a key regulator of inflammatory processes, mediates inflammatory responses associated with Aff3ir-ORF2 deficiency. Aff3ir-ORF2 interacts with Irf5, promoting its retention in the cytoplasm, thereby inhibiting the Irf5-dependent inflammatory pathways. Notably, Irf5 knockdown in Aff3ir-ORF2 deficient mice almost completely rescues the aggravated atherosclerotic phenotype. Moreover, endothelial-specific Aff3ir-ORF2 supplementation using the CRISPR/Cas9 system significantly ameliorated endothelial activation and atherosclerosis. These findings elucidate a novel role for Aff3ir-ORF2 in mitigating endothelial inflammation and atherosclerosis by acting as an inhibitor of Irf5, highlighting its potential as a valuable therapeutic approach for treating atherosclerosis.

    1. Cell Biology
    2. Genetics and Genomics
    Róża K Przanowska, Yuechuan Chen ... Anindya Dutta
    Research Article

    The six-subunit ORC is essential for the initiation of DNA replication in eukaryotes. Cancer cell lines in culture can survive and replicate DNA replication after genetic inactivation of individual ORC subunits, ORC1, ORC2, or ORC5. In primary cells, ORC1 was dispensable in the mouse liver for endo-reduplication, but this could be explained by the ORC1 homolog, CDC6, substituting for ORC1 to restore functional ORC. Here, we have created mice with a conditional deletion of ORC2, which does not have a homolog. Although mouse embryo fibroblasts require ORC2 for proliferation, mouse hepatocytes synthesize DNA in cell culture and endo-reduplicate in vivo without ORC2. Mouse livers endo-reduplicate after simultaneous deletion of ORC1 and ORC2 both during normal development and after partial hepatectomy. Since endo-reduplication initiates DNA synthesis like normal S phase replication these results unequivocally indicate that primary cells, like cancer cell lines, can load MCM2-7 and initiate replication without ORC.